Vilon

Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.

FDA status

Not approved

Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.

FDA: Unapproved drugs

Evidence tier

Human Observational. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 2/5. 3 PubMed citations indexed.

Vilon in the literature

Vilon (Lys-Glu; KE dipeptide) is a synthetic thymus-derived dipeptide bioregulator that binds TCGA DNA sequences and histone H2b, epigenetically modulating gene expression to induce CD4 and CD5 expres

What the literature studies

Immune Research

Evidence tier

Human Observational

Compounding record

Status not verified

Confidence
2/5

Regulatory record

Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.

Regulatory source not verified; no checked date is assigned.

Regulatory context and verification limits are documented below.

Questions

Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.